ArticlemAbs
Response to: monoclonal antibodies targeting CD20.
Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.Neurology · 2020Trial
- Trial
- Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.Annals of neurology · 2018Trial
- Isolation and characterization of human anti-CD20 single-chain variable fragment (scFv) from a Naive human scFv library.Medical oncology (Northwood, London, England) · 2022Article
- Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells.Vaccines · 2022Article
- Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab.Scientific reports · 2019Article
- Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.Frontiers in immunology · 2017Review
- No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
- Comment on
- Comment on
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.